Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis

American Journal of the Medical Sciences

Volumn 341, Issue 1, 2011, Pages 1-9

  Stavrakis, Stavros ^a   Stoner, Julie A ^b   Azar, Madona ^a   Wayangankar, Siddharth ^a   Thadani, Udho ^a,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aspirin; Diabetes; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MEGADOSE; EMBASE; GASTROINTESTINAL HEMORRHAGE; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE;

EID: 78651266855     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181f1fba8     Document Type: Article

References (42)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
3. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003;108:1527-32.
4. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collab-orative Group. Lancet 1988;2:349-60.
5. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5.
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324: 71-86.
7. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136: 161-72.
8. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis ofindividual participant data from randomised trials. Lancet 2009;373: 1849-60.
9. U.S. Preventive Services Task Force. Aspirin for the primary preven-tion of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.
10. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Con-sensus Panel Guide to Comprehensive Risk Reduction for Adult Pa-tients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Com-mittee. Circulation 2002;106:388-91.
11. Redberg RF, Benjamin EJ, Bittner V, et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardio-vascular Nurses Association Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Soci-ety for Women's Health Research. J Am Coll Cardiol 2009;54:1364-405.
12. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010;33:1395-402.
13. Nicolucci A, De Berardis G, Sacco M, et al. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclu-sions. Eur Heart J 2007;28:1925-7.
14. Belch J, MacCuish A, CampbellI, et al. The Prevention of Progres-sion of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.
15. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-41.
16. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531.
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
18. Egger M, Smith GD, Altman D, editors. Systematic reviews in health care. Meta-analysis in context. London (United Kingdom): BMJ Books; 2001.
19. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006;11:193-206.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
21. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
22. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351:233-41.
23. de Gaetano G. Low-dose aspirin and vitamin E in people at cardio-vascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89-95.
24. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hyper-tension: principal results of the Hypertension Optimal Treatment (HOT) randomisedtrial. HOT StudyGroup. Lancet 1998;351:1755-62.
25. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
26. Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264-72.
27. Zanchetti A. Aspirin and antiplatelet drugs in the prevention of cardiovascular complications of diabetes. In: Mogensen CE, editor. Pharmacotherapy of diabetes: new development. New York (NY): Springer; 2007. p. 211-8.
28. Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991;114:835-9
29. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ET-DRS Investigators. JAMA 1992;268:1292-300.
30. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296:313-6.
31. Morimoto T, Fukui T, Lee TH, et al. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med 2004;117:459-68.
32. Ong G, Davis TM, Davis WA. Aspirin is associated with reduced cardiovas-cular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study. Diabetes Care 33:317-21.
33. Welin L, Wilhelmsen L, Bjornberg A, et al. Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study. Pharmacoepidemiol Drug Saf 2009;18:1143-9.
34. Evangelista V, Totani L, Rotondo S, et al. Prevention of cardiovas-cular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 2005;93:8-16.
35. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003;107:2664-9.
36. Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007;154:3-11.
37. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-78.
38. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary preven-tion of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre ran-domised placebo-controlled trial. Lancet 2004;364:685-96.
39. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
40. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
41. Saydah SH, Fradkin J, Cowie CC Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42.
42. De Berardis G, Sacco M, Evangelista V, et al; ACCEPT-D Study Group. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a random-ized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007;8:21.